Channel
@Oncology_Updates
On this record: Topic · Growth · Engagement · Posts · Telegram's recommendations · Cite this entry
1,504subscribers
+40 since we began measuring on 7 August 2026
Risers and fallers across the register · movement among entries of 1,000–3,162.
| Telegram ID | -1001340750770 |
|---|---|
| Type | Channel |
| Username | @Oncology_Updates |
| Created | Between 1 March 2018 and 31 August 2021 — estimated from Telegram’s id allocation, not measured. How this range is calculated. |
| First recorded | 7 August 2026 |
| Last confirmed live | 18 September 2026 |
| Measurements held | 14 |
| Confirmed unchanged | 1 time, most recently 18 September 2026 |
| On Telegram | t.me/Oncology_Updates |
Health & wellness — a classification, not a measurement. An on-box language model (Qwen3.6-35B-A3B-FP8, prompt version 1) read this channel’s own recent posts on 17 September 2026 and assigned it the closest of 31 fixed categories, at 96% confidence. This is a model’s judgement about what the channel is likely to be about, not a fact this register measured the way a subscriber count or a view count is measured — it can be revised on a later pass, and it carries no weight anywhere else on this page. How this classification works, and why it has no browse page of its own yet.
| Measured (UTC) | Subscribers | Change |
|---|---|---|
| 18 Sept 2026, 22:38 | 1,504 | +4 |
| 14 Sept 2026, 19:57 | 1,500 | +3 |
| 5 Sept 2026, 20:16 | 1,497 | +7 |
| 1 Sept 2026, 16:56 | 1,490 | +4 |
| 29 Aug 2026, 19:26 | 1,486 | -1 |
| 26 Aug 2026, 20:03 | 1,487 | +6 |
| 24 Aug 2026, 01:52 | 1,481 | +2 |
| 20 Aug 2026, 16:44 | 1,479 | +2 |
| 17 Aug 2026, 11:43 | 1,477 | -1 |
| 14 Aug 2026, 04:48 | 1,478 | +6 |
| 10 Aug 2026, 23:11 | 1,472 | +5 |
| 8 Aug 2026, 02:44 | 1,467 | +3 |
| 7 Aug 2026, 21:49 | 1,464 | no change |
| 7 Aug 2026, 12:49 | 1,464 | first reading |
20 posts held, back to 3 July 2026 — the reader has not yet reached the start of this channel’s public history, so older posts may sit further back, unread. Read across 1 page of Telegram’s post history, 20 posts per page.
Nothing published in the last 30 days. ERR and ER are rolling 30-day measures, so there is nothing to compute — we hold 20 posts for this entry, the most recent from 6 August 2026. An engagement rate over an empty window would be a number about nothing.
[News] UK–Japan research collaboration for cancers in children and young people https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00392-X/fulltext?rss=yes On July 28, 2026, organisations from the UK and Japan announced a partnership that will provide funding opportunities for international collaborative clinical trials aimed at developing innovative treatments for cancers affecting children and youn…
[News] 2030 hepatitis elimination targets might be missed in Europe https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00393-1/fulltext?rss=yes Europe is set to miss the WHO target to eliminate viral hepatitis as a public health threat by 2030 despite progress in screening because of gaps in vaccination and reaching key populations, according to the European Centre for Disease Prevention and Control …
[News] Sweden plans to restrict PFAS https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00382-7/fulltext?rss=yes On July 23, 2026, the Government of Sweden announced plans to prohibit perfluoroalkyl and polyfluoroalkyl substances (PFAS), also called forever chemicals, in certain consumer products such as clothing, footwear, cosmetics, and kitchen utensils starting Jan 1, 2028. This plan will make Swe…
[News] CARICOM moves towards regional framework for cancer https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00383-9/fulltext?rss=yes The Caribbean Community (CARICOM) is moving towards a regional framework for cancer care after calling for stronger cooperation between members, although questions remain over funding, governance, and implementation. The call followed the 14th Annual Caribbean Associa…
[Policy Review] Local management of second ipsilateral breast cancer events after primary breast-conserving therapy: an international Delphi consensus https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00177-4/fulltext?rss=yes Management of second ipsilateral breast cancer events (iBCEs) remains controversial, and there is a need to collate existing evidence and international guidance on patient sele…
[News] UK study to report cancer risk in armed services personnel https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00375-X/fulltext?rss=yes The UK Government has announced it is to conduct a study into cancer risk in armed services personnel, both past and present. The UK's Ministry of Defence says the study is part of its efforts to improve the long-term health of those who serve and have served i…
[News] First Nations cancer inequalities in Canada https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00349-9/fulltext?rss=yes The expansion of colorectal cancer screening in Ontario, Canada, has coincided with new evidence showing that registered First Nations people experience higher colon cancer incidence at younger ages and poorer survival after breast, cervical, and colon cancer diagnoses than o…
[News] New guidelines to advocate healthy eating and physical activity in school settings in the Americas https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00348-7/fulltext?rss=yes Addressing the persistent increase in rates of overweight, obesity, and physical inactivity in children and adolescents living in the WHO Americas Region, the Pan American Health Organization (PAHO) and the Organization o…
[Comment] A step forward for precision oncology in thyroid cancer https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00254-8/fulltext?rss=yes Radioactive iodine-refractory differentiated thyroid cancer remains a therapeutically challenging disease despite important advances over the last decade. Multi-kinase inhibitors targeting vascular endothelial growth factor receptor (VEGFR) signaling have impro…
[Articles] Efficacy and safety of dabrafenib plus trametinib in adults with differentiated thyroid cancer: a randomised, double-blind, placebo-controlled, phase 3 trial https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00133-6/fulltext?rss=yes In previously-treated patients with locally advanced or metastatic, radioactive iodine-refractory BRAFV600E-positive differentiated thyroid cancer, dabrafenib…
[Comment] Now or later? Switching therapies in metastatic breast cancer https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00332-3/fulltext?rss=yes In contemporary management of patients with hormone receptor-positive, HER2-negative metastatic breast cancer, it is standard to switch therapies at tumour progression, defined by RECIST criteria in clinical trials, and by other measures (many, ironically…
[Articles] Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00287-1/fulltext?rss=yes Switching to camizestrant plus CDK4/6 inhibitor at ESR1 mutat…
Showing the 12 most recent of 20 posts we hold for @Oncology_Updates. View and reaction counts are the latest single reading for each post, not a live figure, and a recent post is still accumulating both. A view count marked ≈ was rounded by Telegram before we ever saw it — t.me prints views in full below 1,000 and to three significant figures above, so ≈1,200,000 means somewhere between 1,150,000 and 1,249,999. Unmarked counts are exact. Text is reproduced from the public post preview and truncated for length.
The reverse of the list above, and a different kind of signal. This does not require this channel to have ever been asked about directly — each row below is a channel we DID ask Telegram about, whose Telegram-generated list happened to include this one. A channel can appear here with an empty list above it, because being named by someone else’s query is independent of having been queried itself.
This channel appears in 1 seed channel's Telegram-generated recommendation list in total. Each is Telegram’s list for THAT channel, not this one — see how this is measured.
A live page changes as we take new readings, so a citation should name the measurement it is based on, not just the URL. The line below cites the subscriber count as measured 18 September 2026 — this entry's latest reading, not the date you are reading this.
“Oncology Updates” (@Oncology_Updates), 1,504 subscribers as measured 18 September 2026. Telegram Register, tgregister.com/channel/Oncology_Updates.
Full measurement history, CC BY 4.0. Every reading this register holds for this entry, not just the latest one, as a dated, downloadable record: CSV · JSON. Free to use with attribution to tgregister.com. Each file carries its own generation timestamp, which is the figure to cite for exactly when the data was retrieved.